Compound Profile
Semaglutide
GLP-1 receptor agonist (prescription drug)
Semaglutide is a GLP 1 receptor agonist, FDA approved as Ozempic, Wegovy, and Rybelsus, backed by a large multi trial Phase 3 program spanning weight management, type 2 diabetes, cardiovascular risk reduction, and kidney outcomes — a categorically stronger evidence tier than the RUO peptides elsewhere in this series.
Last reviewed:
A StrongMonograph visual
Semaglutide
Generated profile category visual
Where to go next — guides & comparisons
Continue reading
- If you want to browse more compounds → All compounds
Prescription-only drug: no consumer sourcing
Semaglutide is an FDA-approved prescription drug (Ozempic, Wegovy, Rybelsus), not a controlled substance, and is not sold as a research peptide. The FDA has determined semaglutide is no longer in shortage, which curtails bulk compounding — compounded access now generally requires individualized, physician-documented clinical necessity.
- Legitimate access is prescription-only through a licensed pharmacy.
- Carries a boxed warning for thyroid C-cell tumor risk; contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2.
- This profile is not a self-treatment guide or a substitute for a prescribing clinician.
Regulatory status
2026 federal and state regulatory context
FDA approved and commercially available by prescription. The FDA has determined semaglutide is no longer in shortage, curtailing 503B outsourcing facilities' ability to compound it in bulk; compounded access now generally requires individualized physician documented clinical necessity rather than cost or availability alone. Not sold as a research peptide.
Regulatory changelog
- 2026: FDA shortage determination resolved for semaglutide, winding down the compounded supply era; 503B bulk compounding no longer available absent individualized clinical justification.
Quick Stats
Evidence level
Strong evidence
Typical onset
Varies by prep
Safety rating
Use extra caution: Use caution
Best for
GLP 1 Receptor Agonism, Glucose Dependent Insulin Secretion, Glucagon Suppression
Avoid / review if
Pregnancy/Breastfeeding, History Of Pancreatitis, Severe Gastrointestinal Disease Or Gastroparesis
Safety & Cautions
Review before use if any apply: Pregnancy/Breastfeeding, History Of Pancreatitis, Severe Gastrointestinal Disease Or Gastroparesis.
Evidence-based safety
Caution when combined
These pairings share a flagged risk mechanism. They are additive-effect cautions derived from contraindication data, not confirmed clinical interactions. Consult a clinician before combining.
Moderate Caution
110 flagged pairingsBlood-sugar lowering
Moderate Caution
110 flagged pairingsBlood-sugar lowering
Browse the grouped cautions below. The list scrolls inside this card when long.
Blood-sugar lowering
- Acarbose
- ajoene
- Allicin
- Aloe Vera
- Alpha-Lipoic Acid
- American Ginseng Extract
- Andrographis
- Anemarrhena Asphodeloides
- Tarragon
- Ashoka
- Astragalus
- Astragalus Membranaceus
- Bael
- Berberis
- Berberis Vulgaris
- Black Seed
- Blueberry
- Buckwheat
- Burdock
- Caraway
- Cichorium Intybus
- Cinnamon
- Cinnamon extract
- Cissus
- Cistanche
- Cistanche Deserticola
- Citrus Bergamia
- Citrus Sinensis
- CJC-1295
- Coenzyme Q10
- Commiphora Mukul
- Coptis
- Coptis Chinensis
- Coriandrum Sativum
- Cornus Officinalis
- Curry Leaf
- D-Mannose
- D-Ribose
- Damiana
- Dandelion
- Dendrobium
- Devils Claw Extract
- Elderberry
- Elecampane
- Eucommia
- Fenugreek
- Fenugreek Extract
- Fingerroot
- Fisetin
- Fucoxanthin
- Garcinia Indica
- Garlic Extract
- Ginkgo Biloba Extract
- Panax Red Ginseng
- Panax White Ginseng
- Glucosamine
- Goldenseal
- Gudmar
- Gymnema
- Holy Basil / Tulsi (Ocimum tenuiflorum)
- Holy Basil Purple
- Holy Basil Seed
- Ipamorelin
- Jujube
- Kuding Tea
- Kudzu
- Banaba
- Luo Han Guo
- Mangifera Indica
- Marshmallow
- MCT Oil
- Bitter Melon
- Morinda Citrifolia
- Moringa
- Morus Alba
- Mulberry Leaf
- Myrtle
- Neem
- Nelumbo Nucifera
- Nettle Root
- Nigella Sativa
- Nicotinamide Mononucleotide
- Notoginseng
- Ocimum Basilicum
- Olive Leaf Extract
- Oregano
- Panax Ginseng Extract
- American Ginseng
- Papaya Leaf
- Phellodendron
- Phellodendron Amurense
- Psyllium
- Pueraria Lobata
- Pycnogenol
- Rehmannia Glutinosa
- Rehmannia Prepared
- Rice Bran
- Rooibos
- Roselle Seed
- Sage
- Salacia
- Serenoa Repens
- Shatavari
- Soursop
- Tamarind
- Tirzepatide
- Tongkat Ali
- Fenugreek
- Wild Yam
- Ashwagandha
Evidence Summary
A StrongEvidence lens
Most useful for practical interpretation when safety context also fits.
StrongStrong evidence
Human clinical evidence: Present in source signals
Mechanistic / preclinical: Mechanism mapped — GLP 1 Receptor Agonism · Glucose Dependent Insulin Secretion · Glucagon Suppression
Research maturity: More interpretable — main contexts: GLP 1 Receptor Agonism · Glucose Dependent Insulin Secretion · Glucagon Suppression
Safety boundary: Safety note available — Review before use if any apply: Pregnancy/Breastfeeding, History Of Pancreatitis, Severe Gastrointestinal Disease Or Gastroparesis.
Evidence Strength
Confidence estimate based on the design quality and consistency of published clinical trials.
Semaglutide has a strong evidence evidence rating.
General wellnessGeneral wellness
Effects
4
How evidence grades work
Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.
A
Strong
Multiple RCTs, consistent direction, adequate effect size
B
Moderate
Some RCTs or consistent observational data in humans
C
Preliminary / Mixed
Animal or in-vitro only, or conflicting human data
D
Traditional / Theoretical
Traditional use only; no controlled human trials
How Semaglutide Works
Simplified mechanism pathway based on preclinical and pharmacological evidence. Does not confirm clinical efficacy.
Mechanism Pathway — How Semaglutide Works
CompoundTarget / ReceptorMechanismEffect / Outcome
Mechanisms & Biological Pathways▼
Preclinical mechanism details from scientific profiles; these represent plausible pathways but do not guarantee clinical efficacy in humans.
GLP 1 Receptor AgonismGlucose Dependent Insulin SecretionGlucagon SuppressionCentral Appetite RegulationIncretin Signaling
Continue exploring
Related research paths
Compare & Sourcing
Compare side-by-side tradeoffs or verify active marker guidelines.
Free safety checklist
Get the Semaglutide evidence notes
Occasional research updates, safety context, and product-quality checks for supplement decisions.
We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.
⚠️ Sourcing Options Disabled for Safety
Direct product recommendations and affiliate links are suppressed for this compound due to its high caution or needs-review safety classification.
Evaluate the safety checks, contraindications, and potential medication interactions below under clinician supervision before use.
Safety first · Harm reduction
This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.
Learn how we evaluate confidence, safety, and intensity on the methodology page.
Editorial Review
Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.
Compound profile context
How to interpret Semaglutide
Semaglutide dosage by use case, onset and duration, safety limits, and interactions for glp 1 receptor agonism, graded against research. Strong Human Evidence… Use this compound profile to understand mechanism, evidence quality, and practical safety context before comparing products or building a stack. A biochemical pathway connection can be useful for discovery, but it is not the same as proven benefit in humans.
When reviewing Semaglutide, separate the active molecule from the product category around it. Dose form, absorption, extract standardization, medication interactions, and individual sensitivity can change the real-world risk-benefit picture.
For supplement planning, avoid combining multiple compounds with overlapping sedating, stimulating, serotonergic, blood-pressure, anticoagulant, or liver-metabolism effects unless a qualified clinician has reviewed the context.